[Future perspectives. From basic research to the development of new therapies aimed at the inhibition of the different stages of signal transduction: applications in breast cancer].
The mechanism implicated in the carcinogenesis are better understood and the transduction of signal is a potential target for new agents. In this review, we describe the different pathways implicated in the transduction of signal and the potential target for new agents in breast cancer.
Campone
Mario
M
CRLCC, Centre René-Gauducheau, bd Jacques-Monod, 44805 Saint-Herblain/Nantes. m-campone@nantes.fnclcc.fr
Kerbrat
Pierre
P
Roché
Henri
H
Bennouna
Jaffar
J
Cuillière
Jean-Claude
JC
Le Mevel
Bernard
B
Fumoleau
Pierre
P
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D035843:Biomedical Research; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000502:physiology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000502:physiology; D015290:Second Messenger Systems; D015398:Signal Transduction / Q000187:drug effects* / Q000502:physiology
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D017346:Protein Serine-Threonine Kinases; D011505:Protein-Tyrosine Kinases; D020794:Receptor Protein-Tyrosine Kinases; D018719:Erb-b2 Receptor Tyrosine Kinases